OBJECTIVE: To investigate nano-hydroxyapatite (nHA) pellets as carriers for vancomycin in the treatment of chronic osteomyelitis and bone defects due to methicillin-resistant Staphylococcus aureus (MRSA) strains. METHODS: Chronic osteomyelitis was induced in 45 New Zealand white rabbits. After 3 weeks (chronic infection), all animals were treated with debridement. The rabbits were divided into an experimental group (the bone was filled with vancomycin-loaded nHA pellets), a control group (the bone was filled with nHA pellets alone), and a blank group. The drug release profiles were determined in vitro and in vivo. X-rays, bone specimens, and microorganism cultures were used to evaluate the efficacy of the treatments. RESULTS: Following a rapid initial release into the circulation, the drug concentration remained effective in the osseous and soft tissues for 12 weeks after debridement. Within 3 months, all rabbits in the experimental group recovered from osteomyelitis without a recurrence of the infection and the bone defects were partially repaired, whereas the infection and bone defects persisted in the control and blank groups. CONCLUSIONS: The results demonstrate that vancomycin-loaded nHA pellets successfully repair bone defects and control infection in MRSA-induced chronic osteomyelitis. In addition, nHA is an effective and safe controlled-release vancomycin carrier for chronic osteomyelitis with bone defects that is induced by MRSA.
OBJECTIVE: To investigate nano-hydroxyapatite (nHA) pellets as carriers for vancomycin in the treatment of chronic osteomyelitis and bone defects due to methicillin-resistant Staphylococcus aureus (MRSA) strains. METHODS:Chronic osteomyelitis was induced in 45 New Zealand white rabbits. After 3 weeks (chronic infection), all animals were treated with debridement. The rabbits were divided into an experimental group (the bone was filled with vancomycin-loaded nHA pellets), a control group (the bone was filled with nHA pellets alone), and a blank group. The drug release profiles were determined in vitro and in vivo. X-rays, bone specimens, and microorganism cultures were used to evaluate the efficacy of the treatments. RESULTS: Following a rapid initial release into the circulation, the drug concentration remained effective in the osseous and soft tissues for 12 weeks after debridement. Within 3 months, all rabbits in the experimental group recovered from osteomyelitis without a recurrence of the infection and the bone defects were partially repaired, whereas the infection and bone defects persisted in the control and blank groups. CONCLUSIONS: The results demonstrate that vancomycin-loaded nHA pellets successfully repair bone defects and control infection in MRSA-induced chronic osteomyelitis. In addition, nHA is an effective and safe controlled-release vancomycin carrier for chronic osteomyelitis with bone defects that is induced by MRSA.
Authors: Masahiro Hasegawa; Akihiro Sudo; Vladimir S Komlev; Serguei M Barinov; Atsumasa Uchida Journal: J Biomed Mater Res B Appl Biomater Date: 2004-08-15 Impact factor: 3.368
Authors: Gráinne M Cunniffe; Glenn R Dickson; Sonia Partap; Kenneth T Stanton; Fergal J O'Brien Journal: J Mater Sci Mater Med Date: 2009-12-20 Impact factor: 3.896
Authors: M S Smeltzer; J R Thomas; S G Hickmon; R A Skinner; C L Nelson; D Griffith; T R Parr; R P Evans Journal: J Orthop Res Date: 1997-05 Impact factor: 3.494
Authors: Luiz Meirelles; Tomas Albrektsson; Per Kjellin; Anna Arvidsson; Victoria Franke-Stenport; Martin Andersson; Fredrik Currie; Ann Wennerberg Journal: J Biomed Mater Res A Date: 2008-12-01 Impact factor: 4.396
Authors: Zaineb A F Albayati; Manjula Sunkara; Suzannah M Schmidt-Malan; Melissa J Karau; Andrew J Morris; James M Steckelberg; Robin Patel; Philip J Breen; Mark S Smeltzer; K Grant Taylor; Kevyn E Merten; William M Pierce; Peter A Crooks Journal: Antimicrob Agents Chemother Date: 2015-12-14 Impact factor: 5.191
Authors: Kushal Vanamala; Katyayani Tatiparti; Ketki Bhise; Samaresh Sau; Marc H Scheetz; Michael J Rybak; David Andes; Arun K Iyer Journal: Drug Discov Today Date: 2020-10-20 Impact factor: 7.851